Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/19/2005DE4444606B4 Verfahren zur Herstellung der Sennoside A und B Process for the preparation of sennosides A and B.
05/19/2005DE10349512A1 Use of 1,4-naphthoquinone derivatives as inhibitors of aspartyl protease, for treatment of infection by Candida or human immune deficiency virus
05/19/2005DE10349511A1 Using fungal naphthopyran-8,9-diones as inhibitors of aspartyl protease, useful for treatment of infection by Candida or human immune deficiency virus
05/19/2005DE10349175A1 Mittel zur Gewichtsreduktion Means for weight loss
05/19/2005DE10348298A1 Amidomethyl-substituierte 2-(4-Sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel Amidomethyl-substituted 2- (4-sulphonylamino) -3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, processes and intermediates for their preparation containing these compounds and pharmaceutical
05/19/2005DE10348044A1 Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen Dual-alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
05/19/2005DE10348023A1 Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen New alanyl aminopeptidase inhibitors for functional interference of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
05/19/2005DE10148828B4 Modulation der Expression STAT-1-abhängiger Gene Modulating the expression of STAT-1-dependent genes
05/19/2005CA2710829A1 Uses of adenosine a2a receptor antagonists
05/19/2005CA2559017A1 Phenylpropanoic derivatives and compositions containing same, which stimulate libido and the associated physiological mechanisms
05/19/2005CA2551056A1 Benzo[b][1,4]dioxepine derivatives
05/19/2005CA2549969A1 Alkynes ii
05/19/2005CA2549967A1 Alkynes i
05/19/2005CA2549965A1 Alkynes iii
05/19/2005CA2545100A1 Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators
05/19/2005CA2544965A1 Heat moisture treated starch for the treatment of hypoglycaemia
05/19/2005CA2544924A1 Methods and compositions for treating mcp-1 related pathologies
05/19/2005CA2544900A1 Delta-9- the treatment of multiple sclerosis
05/19/2005CA2544863A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
05/19/2005CA2544845A1 Preparation of pharmaceutical salts of [1, 4] - bipiperidine
05/19/2005CA2544843A1 Chewable tablet
05/19/2005CA2544755A1 A stabilized azithromycin composition
05/19/2005CA2544752A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
05/19/2005CA2544748A1 Allosteric modulators of metabotropic glutamate receptors
05/19/2005CA2544678A1 Modulators of cellular adhesion
05/19/2005CA2544344A1 Pharmaceutical formulations of a quinolone antibiotic containing flavouring substances with improved pharmaceutical properties
05/19/2005CA2544258A1 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
05/19/2005CA2544235A1 Dialysates and methods and systems related thereto
05/19/2005CA2544213A1 Imidazo[1,2-a]pyridine anxiolytics
05/19/2005CA2544145A1 Composition and method for treating macular degeneration
05/19/2005CA2543956A1 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
05/19/2005CA2543943A1 2-azetidinones as anti-hypercholesterolemic agents
05/19/2005CA2543829A1 Compositions and methods for treatment of nervous system disorders
05/19/2005CA2543707A1 Nitrogen-containing fused heterocyclic compounds
05/19/2005CA2543643A1 Pyridine carboxylic acid derivatives as glucokinase modulators
05/19/2005CA2543618A1 Cytokine inhibitory drugs for treatment of macular degeneration
05/19/2005CA2543611A1 Methods of lowering lipid levels in a mammal
05/19/2005CA2543610A1 Transdermal analgesic systems having reduced abuse potential
05/19/2005CA2543602A1 Triazole compounds and uses related thereto
05/19/2005CA2543508A1 Controlled release analgesic suspensions
05/19/2005CA2543199A1 Use of crth2 antagonist compounds in therapy
05/19/2005CA2543172A1 Stable lansoprazole formulation
05/19/2005CA2543166A1 Ph sensitive prodrugs of 2,6-diisopropylphenol
05/19/2005CA2543164A1 Combination of proton pump inhibitor and sleep aid
05/19/2005CA2543160A1 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
05/19/2005CA2543132A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
05/19/2005CA2543116A1 Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
05/19/2005CA2543115A1 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
05/19/2005CA2543045A1 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
05/19/2005CA2543030A1 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
05/19/2005CA2543029A1 Rna interference mediated inhibition of gpra and aaa1 gene expression using short nucleic acid (sina)
05/19/2005CA2543013A1 Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina)
05/19/2005CA2543003A1 Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer
05/19/2005CA2542878A1 Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists
05/19/2005CA2542835A1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
05/19/2005CA2542602A1 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
05/19/2005CA2542527A1 Rna interferance mediated inhibition of cholinergic muscarinic receptor (chrm3) gene expression using short interfering nucleic acid /sina)
05/19/2005CA2542509A1 Salts of pharmacologically active compounds
05/19/2005CA2542142A1 Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis
05/19/2005CA2541643A1 Rna interference mediated inhibition of hairless (hr) gene expression using short interfering nucleic acid (sina)
05/19/2005CA2541493A1 Process for production of essentially solvent-free small particles
05/19/2005CA2541212A1 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/19/2005CA2540704A1 Benzoimidazole compounds
05/19/2005CA2538218A1 Compositions of botanical extracts for cancer therapy
05/19/2005CA2537118A1 Composition for topical use containing an extract of stryphnodendron, its preparation and its application
05/19/2005CA2534995A1 The use of plp with peg-rmetase in vivo for enhanced efficacy
05/19/2005CA2534069A1 Methods of reducing risk of infection from pathogens
05/18/2005EP1531181A2 Therapeutic oligonucleotides targeting the human mdr1 and mrp genes
05/18/2005EP1531168A1 Process for the removal of porogens from temperature sensitive macroreticular polymers using steam at reduced pressure
05/18/2005EP1531158A1 Lipid A and topic, in particular cosmetic, composition thereof
05/18/2005EP1531156A1 Method for synthesis of silylated ascorbic acid derivatives
05/18/2005EP1531153A1 Epothilone derivatives
05/18/2005EP1531152A1 Process for purification of climbazol
05/18/2005EP1530973A2 Methods for inducing T cell tolerance to a tissue or organ graft
05/18/2005EP1530969A1 Combination chemotherapy
05/18/2005EP1530968A1 Galangin components for the maintenance of bone health and/or treatment, alleviaton and/or prevention of bone disorder
05/18/2005EP1530965A1 Controlled release delivery system of sexual hormones for nasal application
05/18/2005EP1530725A1 Materials and methods for inductions of immune tolerance
05/18/2005EP1530724A2 Diagnosis and prevention of cancer cell invasion
05/18/2005EP1530720A2 Breast cancer eradication program
05/18/2005EP1530636A1 Treatment of melanoma by reduction in clusterin levels
05/18/2005EP1530632A2 Growth factor which acts through erb b-4 rtk
05/18/2005EP1530593A1 Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof
05/18/2005EP1530584A2 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
05/18/2005EP1530574A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
05/18/2005EP1530573A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors
05/18/2005EP1530570A2 CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
05/18/2005EP1530568A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE
05/18/2005EP1530567A1 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
05/18/2005EP1530565A1 Substituted thiophene carboxamide compounds for the treatment of inflammation
05/18/2005EP1530562A1 Optically active 1-(fluoro-,trifluoromethyl-or trifluoromethoxy-substituted phenyl)alkylamine n-monoalkyl derivatives and process for producing same
05/18/2005EP1530559A1 Method and device for producing formic acid formates and use of said formates
05/18/2005EP1530494A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease
05/18/2005EP1530480A2 Cosmetic composition comprising monosaccharides or polysaccharides, uses and treatment methods
05/18/2005EP1530479A2 Medicament, food supplement, and fodder additive
05/18/2005EP1530478A2 Exemestane for first-line treatment of breast cancer
05/18/2005EP1530476A1 Use of reboxetine for the treatment of hot flashes
05/18/2005EP1530475A2 Pharmaceutical compositions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
05/18/2005EP1530474A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors
05/18/2005EP1530473A2 Regulation of erythrocyte apoptosis
1 ... 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 ... 7860